A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

Phase 2 Completed NCT05039450

Condition	NASH - Nonalcoholic Steatohepatitis
Phase	Phase 2
Sponsor	Akero Therapeutics, Inc
Status	Completed
Enrollment	213 participants
Interventions	EFX
Start date	Jul 30, 2021
Completion date	Dec 15, 2023
Results posted	Jul 21, 2026

Summary

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.

Main: Change From Baseline in Fibrosis With no Worsening Steatohepatitis Assessed by NASH CRN System

Week 36 · Participants

Placebo (Main Study)	8 Participants
EFX 28 mg (Main Study)	10 Participants
EFX 50 mg (Main Study)	12 Participants
Placebo (Main Study)	49 Participants
EFX 28 mg (Main Study)	36 Participants
EFX 50 mg (Main Study)	39 Participants

p-value	0.3775
Point estimate percentage difference	6.73 (95% CI -8.77–22.24)

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.
Vitamin E Dosing Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.

English 한국어 日本語中文 Русский